On March 2, seven members of Congress who are also physicians sent a letter to HHS urging the department to revise its COVID-19 vaccine emergency use authorization to be “based on all available clinical data.” The lawmakers said such a revision could lead to an endorsement of single-dose regimens for Pfizer and Moderna vaccines, which could speed up the nation’s COVID-19 vaccination effort.
However, government scientists have said there is not enough reliable data to justify single-dose regimens for Pfizer and Moderna vaccines. They said although single doses of these vaccines may offer short term-protection from COVID-19, they are designed to give recipients long-term protection only after two doses, according to the Journal.
“It is essential that these vaccines be used as authorized by FDA in order to prevent Covid-19 and related hospitalizations and death,” Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, told the Journal.
More articles on pharmacy:
Amgen acquires cancer drugmaker for $1.9B
Moderna vaccine causing delayed rash in some recipients, small study says
Drugmakers studying how to administer COVID-19 vaccines without a needle
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
